Do I Need to Stop My SSRI Before Taking Psychedelics?

Evidence reviewed: September 27, 2026.

You take an SSRI. Maybe it has helped you get your footing. Maybe it helps, but something still feels unresolved. You are curious about psychedelics, and you keep finding the same instruction: stop your antidepressant first.

Older guidance and many research protocols required tapering. There were concerns about interactions and whether antidepressants would weaken the experience. But stopping a medication that is helping is a real decision, with its own risks. A research requirement is not proof that everyone needs to do it. Goodwin and colleagues, 2023.

You do not automatically need to stop an SSRI. That does not mean every combination is safe. The useful question is what the evidence says about your medication, the particular substance, and your current health.

Two questions that often get mixed together

The studies below measure different things: what people feel, drug concentrations, adverse effects, and sometimes depression symptoms. Those outcomes are related, but they are not interchangeable.

The evidence differs by substance

Psilocybin: encouraging findings, with limits

In a randomized crossover study, 23 healthy participants completed psilocybin sessions after two weeks of escitalopram or placebo. Escitalopram did not meaningfully reduce positive mood effects; some unpleasant effects and anxiety were reduced. The study did not find increased serotonin toxicity. Two weeks in screened healthy volunteers is not the same as years of treatment in someone with a complex history. Becker and colleagues, 2022.

A separate study followed 19 people with treatment-resistant depression who continued an SSRI during supported psilocybin treatment. Depression scores improved, and no serious treatment-emergent adverse events were reported. But it was small, uncontrolled and followed people for only three weeks. It cannot establish that continuing and stopping an SSRI produce equivalent results. Goodwin and colleagues, 2023.

An online survey also found reports of weaker mushroom effects during SSRI use, sometimes persisting after discontinuation. Reports based on memory, expectations and unstandardized mushrooms cannot predict your response or tell you how long to wait. Gukasyan and colleagues, 2023.

LSD: an SSRI does not always block it

A 2025 randomized crossover study in 23 healthy participants tested LSD after six weeks of paroxetine. Pleasant subjective effects were not reduced, while anxiety and some unpleasant effects were lower. Paroxetine increased LSD exposure in the blood. This is evidence about one SSRI under controlled conditions, not permission to generalize across medications or settings. Becker and colleagues, 2025.

MDMA: a different interaction

MDMA depends substantially on serotonin transporters, which SSRIs block. In a controlled study of 12 healthy men, paroxetine markedly reduced MDMA’s subjective effects despite increasing MDMA blood concentrations. Feeling less does not necessarily mean less drug is present. This study did not test therapeutic outcomes in people taking long-term SSRIs. Farré and colleagues, 2007.

A 2026 drug-death analysis found antidepressants were less often detected in MDMA deaths than in other drug-related deaths; prescribed antidepressant use had no statistically significant association. Because it compared deaths rather than following living users, it cannot establish that combining the drugs protects someone or is safe. Rock and colleagues, 2026.

Overall, these findings challenge a blanket tapering rule. They do not settle the question for every person. Small, selected studies cannot reliably exclude rare serious harms or account for complex medication combinations.

01

Physical safety

Could this combination cause harm, given my health and other medications?

02

The experience

Could it reduce or alter what I feel? A muted effect is not a signal to take more.

Stopping has its own risks

Abrupt discontinuation, missed doses or rapid reductions can cause withdrawal: dizziness, nausea, disturbed sleep, anxiety, irritability and electric-shock sensations sometimes called “brain zaps.” Symptoms vary; some are brief, while others are severe or prolonged. NICE recommends an agreed, staged reduction when stopping is appropriate, with monitoring and a pace responsive to symptoms. NICE guidance.

The condition being treated can also return or worsen. Withdrawal and recurrence can overlap, so new distress should not automatically be read as proof that you need the medication forever—or that you should push through without it. A clinician can help assess the timing and pattern. Royal College of Psychiatrists.

If an SSRI is helping you sleep, function and stay connected, that stability belongs in the calculation. An uncertain psychedelic benefit needs to be weighed against what you might lose by changing treatment.

Do not try to overcome blunting by taking more

There is no validated home-use conversion from “I take an SSRI” to “I need more psychedelic.” Responses vary, and the LSD and MDMA studies show that subjective intensity can diverge from blood exposure. Increasing the amount to chase an expected effect is therefore an unsafe, unpredictable workaround. A muted experience is not a reliable signal to add more. LSD interaction study; MDMA interaction study.

When the conversation needs more caution

• Bipolar disorder or psychosis vulnerability: including a personal or relevant family history. Screening guidance treats these as important concerns; reassuring results from selected participants do not establish safety here. Research safety guidance.
• Suicidality, clinical instability or significant medical conditions: these call for assessment before planning an experience. A 2026 trial excluded high suicide risk, bipolar and psychotic disorders, and medical problems incompatible with treatment. Trial results should not be extended to those excluded groups. Rucker and colleagues, 2026.
• Lithium: reports describe seizures with classic psychedelics. These self-selected reports cannot give a reliable incidence, but the signal warrants particular caution. Stopping lithium to make room for a psychedelic is not a solution to improvise. Nayak and colleagues, 2021.
• MAOIs and complex medication combinations: MAOIs are different from SSRIs; fatal serotonin toxicity has been reported with MDMA and moclobemide. Multiple prescriptions, non-prescription drugs and supplements need a full interaction review, not an SSRI-only check. Pilgrim and colleagues, 2012.

Work through the decision

1. Name what you want. Relief from depression? Curiosity? A different perspective? Write it down. Consider other ways to work toward that goal, including improving your current care.
2. Consider how you are doing. How have sleep, mood, relationships and daily functioning been? What happened during previous medication changes? Is this a steady period or a crisis?
3. Make the question specific. List your medications, supplements, recent changes and the substance you are considering. “Psychedelics and antidepressants” is too broad for a useful answer.
4. Compare the options. Discuss continuing treatment and postponing the experience, seeking a properly supervised assessment, or reviewing medication for its own clinical reasons. A booked date is not a reason to rush a taper.
5. Plan support and follow-up. Who would notice a change in your sleep or behaviour? Who could you call? What time and support would you have afterward? Use Entheo’s Preparation Guidebook and integration resources to make those questions concrete.

Questions to bring to your prescriber

Your prescriber may not specialize in psychedelics. They can still help assess your treatment history and stopping risks. Bring the relevant studies and ask:

• What is my SSRI doing for me now, and what is my risk of recurrence if it changes?
• Does the evidence involve my medication and the substance I am considering?
• Do my diagnoses, family history or other medications change the assessment?
• If a medication review is appropriate independently of psychedelics, how would we monitor it and respond to problems?
• What would make us postpone, and who could provide a specialist or pharmacist review?

Bring Entheo’s medical-screening questions as a discussion aid, not a pass/fail test. The aim is an informed plan, not simply permission.

Already tapering or recently stopped?

Tell your prescriber what you changed, when, and what has happened to sleep, mood and physical symptoms. Ask for a review before further changes; do not accelerate a taper to meet a trip date. If symptoms are worsening, postpone the psychedelic plan and seek assessment. Do not use a psychedelic to test whether withdrawal is over. NICE guidance.

New suicidal thoughts need prompt help, whether they reflect withdrawal or recurrence. Contact your prescriber urgently; if you cannot stay safe, seek emergency help now. Royal College of Psychiatrists.

What to remember

Tapering is not universally required. Combining is not universally safe. Consider how your current treatment is helping. Do not stop abruptly or take more to overcome blunting. Get specific about the medication, substance, risks and support before deciding what comes next.

For the full medication review, including medicines other than SSRIs, see Medication considerations. Do not abruptly stop prescribed medication or increase a psychedelic dose to compensate for reduced effects.